Lupin Manufacturing Solutions Repositions Assets and Leverages India’s API Ecosystem for CDMO Growth

Lupin Manufacturing Solutions (LMS) is strategically aligning its long-term plans to capitalize on CDMO opportunities by repositioning core assets, investing in novel treatment methods, and leveraging India’s API ecosystem. Dr. Abdelaziz Toumi, CEO of LMS, outlined the company’s approach to Viveka Roychowdhury. LMS is actively working to reposition key assets to meet market demands, while also directing investments towards new modalities to stay at the forefront of pharmaceutical innovation. Furthermore, the company plans to fully utilize India’s existing API infrastructure to maximize efficiency and cost-effectiveness in its manufacturing processes. This strategy aims to position LMS as a key player in the CDMO landscape, capitalizing on both internal strengths and external opportunities within the pharmaceutical industry.

Newsflash | Powered by GeneOnline AI
Date: May 9, 2025

Related posts:

Restricting Flavored E-Cigarettes Cuts Vaping Rates but Raises Smoking Rates for Young Adults, Study Finds Study Reveals Telemedicine Could Curtail Unnecessary Medical Testing Study Reveals Antibiotic-Resistant Pathogens on Skin of Nursing Home Residents Misdiagnosis of Autoimmune Diseases as Psychosomatic Disorders Causes Long-Term Harm

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後